BNP Paribas Financial Markets Makes New $802,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)

BNP Paribas Financial Markets acquired a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 151,906 shares of the company's stock, valued at approximately $802,000. BNP Paribas Financial Markets owned approximately 0.74% of Protara Therapeutics as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. HBK Investments L P acquired a new position in Protara Therapeutics in the fourth quarter valued at about $106,000. Dimensional Fund Advisors LP acquired a new stake in shares of Protara Therapeutics during the fourth quarter worth about $111,000. Bailard Inc. bought a new position in shares of Protara Therapeutics during the 4th quarter valued at about $157,000. Commonwealth Equity Services LLC lifted its holdings in shares of Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after purchasing an additional 17,572 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new position in shares of Protara Therapeutics in the 4th quarter valued at approximately $330,000. Institutional investors own 38.13% of the company's stock.

Insider Buying and Selling

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total value of $96,144.72. Following the completion of the transaction, the insider now directly owns 98,861 shares in the company, valued at $447,840.33. This trade represents a 17.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on TARA shares. Scotiabank began coverage on shares of Protara Therapeutics in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Protara Therapeutics in a report on Friday, March 14th. They set an "overweight" rating on the stock. Lifesci Capital assumed coverage on shares of Protara Therapeutics in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $23.00 target price on shares of Protara Therapeutics in a report on Monday, April 28th. Finally, Jones Trading raised Protara Therapeutics to a "strong-buy" rating and set a $21.00 price target on the stock in a research note on Thursday, May 22nd. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $20.50.

Protara Therapeutics Trading Up 1.0%

Shares of NASDAQ TARA traded up $0.03 during midday trading on Tuesday, reaching $3.16. The company's stock had a trading volume of 242,764 shares, compared to its average volume of 770,859. The stock has a 50 day simple moving average of $3.77 and a 200-day simple moving average of $4.17. The stock has a market capitalization of $121.92 million, a price-to-earnings ratio of -1.12 and a beta of 1.73. Protara Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.18. As a group, equities analysts anticipate that Protara Therapeutics, Inc. will post -3.32 EPS for the current year.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.